Kun Wang

Kun Wang

Auto-generated profile, based on publicly available information

Kun Wang

Peking University Cancer Hospital 3

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in Cancer Medicine
Verified
Journal Article
Open access
YSYu‐Ming Su
Yu‐Ming Su
WLWei Liu
Wei Liu
XYXiao‐Luan Yan
Xiao‐Luan Yan
LWLi‐Jun Wang
Li‐Jun Wang
MLMing Liu
Ming Liu
BXBaocai Xing
Baocai Xing
Background: Patients with a 5‐year recurrence‐free survival post liver resection for colorectal cancer liver metastases (CRLM) are considered to be potentially cured. However, there is a deficit of data on long‐term follow‐up and the recurrence status among these patients in the Chinese population. We analyzed real‐world follow‐up data of patients with CRLM who underwent hepatectomy, explored the recurrence patterns, and established a prediction model for a potential cure scenario.Methods: Patients who underwent radical hepatic resection for CRLM during 2000–2016, with actual follow‐up data for at least 5 years, were enrolled. The observed survival rate was calculated and compared among the groups with different recurrence patterns. The predictive factors for 5‐year non‐recurrence were determined using logistic regression analysis; a recurrence‐free survival model was developed to predict long‐term survival.Results: A total of 433 patients were included, of whom 113 patients were found non‐recurrence after 5 years follow‐up, with a potential cure rate of 26.1%. Patients with late recurrence (>5 months) and lung relapse showed significantly superior survival. Repeated localized treatment significantly improved the long‐term survival of patients with intrahepatic or extrahepatic recurrences. Multivariate analysis showed that RAS wild‐type CRC, preoperative CEA <10 ng/ml, and liver metastases ≤3 were independent factors for a 5‐year disease‐free recurrence. A cure model was developed based on the above factors, achieving good performance in predicting long‐term survival.Conclusions: About one quarter patients with CRLM could achieve potential cure with non‐recurrence at 5‐year after surgery. The recurrence‐free cure model could well distinguish the long‐term survival, which would aid clinicians in determining the treatment strategy.

15 April 2025 in IEEE Transactions on Computational Social Systems
Verified
Journal Article
Closed access
XWXiaohua Wan
Xiaohua Wan
YHYulong Hu
Yulong Hu
DQDehui Qiu
Dehui Qiu
RLRui Li
Rui Li
LDLiguo Deng
Liguo Deng
KWKun Wang
Kun Wang
Colorectal cancer (CRC) is a prevalent malignancy with significant social and healthcare implications, ranking among the top causes of cancer-related mortality worldwide. In this computational social systems context, we address the challenge of accurately segmenting CRC lesions from colonoscopy images, which is pivotal for early cancer detection and treatment. The complexity of intestinal environments and variations in medical expertise contribute to the high rate of undetected or misdiagnosed lesions, underscoring the need for advanced computational models. This study presents ColoSegNet, a novel self-supervised deep learning framework designed to enhance the accuracy and effectiveness of CRC diagnosis. By leveraging a comprehensive and annotated colorectal lesion segmentation dataset (CLSD), ColoSegNet incorporates a temporal correlation module to extract critical features from colonoscopy video frames, significantly improving the segmentation of colorectal lesions. Furthermore, ColoSegNet employs a masked autoencoder (MAE) module for self-supervised image reconstruction, preserving the original image integrity and facilitating precise segmentation. Comparative assessments against established models such as UNet, PraNet, and Deeplab V3 demonstrate ColoSegNet’s superior performance in detailed feature representation and overall segmentation accuracy. This research not only contributes to the field of medical imaging but also to computational social systems, by capturing inherent data patterns and integrating specialized modules for feature representation in a healthcare context. Our findings provide valuable insights into the early and accurate detection of CRC, a critical issue given the disease’s high incidence and mortality rates, and its impact on social systems.

30 June 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
HWHongzhi Wang
Hongzhi Wang
KWKun Wang
Kun Wang
XZXuan Zheng
Xuan Zheng
DDDezuo Dong
Dezuo Dong
XZXianggao Zhu
Xianggao Zhu
WWWei-Hu Wang
Wei-Hu Wang
PURPOSE: Given the underexplored combination of immune checkpoint inhibitors, tyrosine kinase inhibitors (TKIs), and radiotherapy in locally advanced, unresectable hepatocellular carcinoma (HCC), this study aimed to evaluate camrelizumab (a PD-1 inhibitor), apatinib (a TKI), and intensity-modulated radiotherapy (IMRT) for this setting and identify potential biomarkers. PARTICIPANTS AND METHODS: This single-arm phase 2 trial enrolled locally advanced, unresectable HCC patients who were systemic treatment-naïve or refractory/intolerant to first-line targeted therapy. Patients received IMRT (50-60 Gy) to all lesions plus camrelizumab (200 mg intravenously every 3 weeks) and apatinib (250 mg orally once daily) for up to 2 years. Primary endpoint was progression-free survival (PFS); secondary endpoints included response, overall survival (OS), and safety. RESULTS: Between October, 2020, and November, 2024, 44 patients were enrolled. 40 patients (90.9%) had BCLC stage C disease, including macrovascular invasion in 36 (81.8%) and lymph node spread in 11 (25.0%) cases. Objective response rate was 84.1%. The median PFS was 13.8 months and median OS was not reached. The 24-month PFS rate was 38.1% and OS rate was 70.2%, respectively. Grade 3-4 treatment-related adverse events occurred in 36 patients (81.8%), the most common being thrombocytopenia (36.4%) and hypertension (29.5%). No treatment-related deaths were observed. TP53 mutation in circulating tumor DNA was associated with worse clinical outcomes. CONCLUSION: Camrelizumab and apatinib with radiotherapy demonstrated encouraging efficacy with manageable toxicity in locally advanced, unresectable HCC, warranting randomized trials validation.

15 September 2026
Verified
Other
Open access
PDF file
HWHongzhi Wang
Hongzhi Wang
KWKun Wang
Kun Wang
XZXuan Zheng
Xuan Zheng
DDDezuo Dong
Dezuo Dong
XZXianggao Zhu
Xianggao Zhu
WWWei-Hu Wang
Wei-Hu Wang
Supplementary Table 1-12 and Supplementary Figure 1-9


15 September 2026
Verified
Other
Open access
HWHongzhi Wang
Hongzhi Wang
KWKun Wang
Kun Wang
XZXuan Zheng
Xuan Zheng
DDDezuo Dong
Dezuo Dong
XZXianggao Zhu
Xianggao Zhu
WWWei-Hu Wang
Wei-Hu Wang
Purpose:Given the underexplored combination of immune checkpoint inhibitors, tyrosine kinase inhibitors (TKI), and radiotherapy in locally advanced, unresectable hepatocellular carcinoma (HCC), this study aimed to evaluate camrelizumab (a programmed cell death protein 1 inhibitor), apatinib (a TKI), and intensity-modulated radiotherapy (IMRT) for this setting and identify potential biomarkers. Patients and Methods:This single-arm phase II trial enrolled patients with locally advanced, unresectable HCC who were systemic treatment-naïve or refractory/intolerant to first-line targeted therapy. Patients received IMRT (50–60 Gy) to all lesions plus camrelizumab (200 mg intravenously every 3 weeks) and apatinib (250 mg orally once daily) for up to 2 years. The primary endpoint was progression-free survival (PFS); secondary endpoints included response, overall survival (OS), and safety. Results:Between October 2020 and November 2024, 44 patients were enrolled. Forty patients (90.9%) had Barcelona Clinic Liver Cancer stage C disease, including macrovascular invasion in 36 (81.8%) and lymph node spread in 11 (25%) cases. The objective response rate was 84.1%. The median PFS was 13.8 months, and the median OS was not reached. The 24-month PFS rate was 38.1%, and the OS rate was 70.2%. Grade 3 to 4 treatment-related adverse events occurred in 36 patients (81.8%), the most common being thrombocytopenia (36.4%) and hypertension (29.5%). No treatment-related deaths were observed. TP53 mutation in circulating tumor DNA was associated with worse clinical outcomes. Conclusions:Camrelizumab and apatinib with radiotherapy demonstrated encouraging efficacy with manageable toxicity in locally advanced, unresectable HCC, warranting randomized trials for validation.